331 related articles for article (PubMed ID: 12170084)
41. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors.
Minervini MI; Demetris AJ; Lee RG; Carr BI; Madariaga J; Nalesnik MA
Mod Pathol; 1997 Jul; 10(7):686-92. PubMed ID: 9237179
[TBL] [Abstract][Full Text] [Related]
42. Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: its role as a diagnostic marker.
Lee HS; Kim WH; Kang GH
J Korean Med Sci; 2003 Dec; 18(6):842-8. PubMed ID: 14676441
[TBL] [Abstract][Full Text] [Related]
43. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver.
Ma CK; Zarbo RJ; Frierson HF; Lee MW
Am J Clin Pathol; 1993 May; 99(5):551-7. PubMed ID: 7684185
[TBL] [Abstract][Full Text] [Related]
44. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
45. Do CA 19-9 and TPA play a minor role as compared to AFP in diagnosing primary hepatocellular carcinoma?
Leandro G; Zizzari S; Fabris C; Basso D; Elba S; Del Favero G; Meggiato T; Angonese C; Di Mario F; Manghisi OG
Oncology; 1989; 46(6):381-5. PubMed ID: 2479897
[TBL] [Abstract][Full Text] [Related]
46. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
Lamps LW; Folpe AL
Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
[TBL] [Abstract][Full Text] [Related]
47. Hepatocellular carcinoma with mesothelioma-like dissemination.
Otsuki Y; Shimizu S; Hosoda Y; Nagasawa M; Sato Y; Kobayashi H
Pathol Int; 2005 Nov; 55(11):738-44. PubMed ID: 16271087
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics.
Wee A
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):266-72. PubMed ID: 16932016
[TBL] [Abstract][Full Text] [Related]
49. Utility of polyclonal and monoclonal antibodies against carcinoembryonic antigen in hepatic fine-needle aspirates.
Rishi M; Kovatich A; Ehya H
Diagn Cytopathol; 1994 Dec; 11(4):358-61; discussion 361-2. PubMed ID: 7895575
[TBL] [Abstract][Full Text] [Related]
50. Immunocytochemical evaluation of liver fine-needle aspirations.
Bedrossian CW; Davila RM; Merenda G
Arch Pathol Lab Med; 1989 Nov; 113(11):1225-30. PubMed ID: 2479356
[TBL] [Abstract][Full Text] [Related]
51. Aberrant expression of a fetal glycoprotein 68 in hepatocellular carcinoma: a comparative study on the expression of alpha-fetoprotein and carcinoembryonic antigen.
Kato M; Shinozawa T; Kato S; Terada T
Histol Histopathol; 2004 Jul; 19(3):701-6. PubMed ID: 15168330
[TBL] [Abstract][Full Text] [Related]
52. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Leong AS; Sormunen RT; Tsui WM; Liew CT
Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
[TBL] [Abstract][Full Text] [Related]
53. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.
Proca DM; Niemann TH; Porcell AI; DeYoung BR
Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):120-5. PubMed ID: 10937059
[TBL] [Abstract][Full Text] [Related]
54. Carcinoembryonic antigen and alpha-fetoprotein expression and monoclonal antibody targeting in a human hepatoma/nude mouse model.
Wang ZF; Stein R; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):869s-872s. PubMed ID: 1688735
[TBL] [Abstract][Full Text] [Related]
55. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma.
Haratake J; Hashimoto H
Liver; 1995 Feb; 15(1):9-15. PubMed ID: 7539881
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical study on hepatic tumors--KM01 stains compared with AFP, CEA, CA19-9 and RAS P21.
Hanabata M; Ohyanagi H; Saitoh Y; Itoh H
Kobe J Med Sci; 1991 Apr; 37(2):81-96. PubMed ID: 1717740
[TBL] [Abstract][Full Text] [Related]
57. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern.
Kumagai I; Masuda T; Sato S; Ishikawa K
Hepatol Res; 2001 Jul; 20(3):312-319. PubMed ID: 11404191
[TBL] [Abstract][Full Text] [Related]
58. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections.
Balaton AJ; Nehama-Sibony M; Gotheil C; Callard P; Baviera EE
J Pathol; 1988 Dec; 156(4):305-10. PubMed ID: 2465399
[TBL] [Abstract][Full Text] [Related]
59. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique.
Pan CC; Chen PC; Tsay SH; Ho DM
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):347-52. PubMed ID: 16280664
[TBL] [Abstract][Full Text] [Related]
60. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
